Subsidiary of Aurobindo Pharma receives USFDA’s final approval for Carboprost Tromethamine Injection!
Shares of the company have gained more than 35% on a YTD basis.
Product has an estimated market size of around $51.4 million
Aurobindo Pharma’s wholly owned subsidiary company - Eugia Pharma Specialties has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Carboprost Tromethamine Injection USP 250 mcg/mL, Single-Dose Vials, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Hemabate Injection, 250mcg/mL, of Pfizer Inc. The product is expected to be launched in June 2023.
The approved product has an estimated market size of around $51.4 million for the twelve months ending March 2023, according to IQVIA. This is the 159th approved ANDA (including 8 tentative approvals received) out of Eugia Pharma Specialty Group (EPSG) facilities, manufacturing both oral and sterile speciality products.
Share price movement of Aurobindo Pharm Limited
Today, the stock opened at Rs 599.55, with a high and low of Rs 606.85 and Rs 596.45. Currently, the stock is trading at Rs 604.45, down by 0.12%.
In the last six months, the shares of the company have given about 28 per cent returns and in the last 1 year, the stock has given about 10% returns.
The stock has a 52-week high of Rs 647.90 and a 52-week low of Rs 397.30. The company has a ROCE of 12.9% and an ROE of 11.7% with a market capitalisation of Rs 35,420 crore.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments. Aurobindo Pharma is India’s second-largest pharma company & Largest generics company in the US.
Start Investing in 5 mins*
Rs. 20 Flat Per Order | 0% Brokerage
About the Author
DisclaimerInvestment/Trading in securities Market is subject to market risk, past performance is not a guarantee of future performance. The risk of loss in trading and investment in Securities markets including Equites and Derivatives can be substantial.
Open Free Demat Account
By proceeding, you agree to the T&C.
Sahana Systems IPO worth ₹32.74 crore comprises entirely of a fresh issue of shares by the company. The price band has been fixed in the range of ₹132 to ₹135.
- Jun 06, 2023
Infollion Research Services IPO worth Rs.21.45 crore, comprises of a fresh issue and an offer for sale (OFS) by promoters and early shareholders. The price band has been fixed in the range of Rs80 to Rs82.
- Jun 06, 2023
Fill in your details below: